Among them, TRPV1 exerts context‐dependent dual actions within the evolving MS lesion, while TRPM2, TRPM4, TRPM7, and TRPV4 consistently drive detrimental inflammatory responses. This evidence concerns the gene TRPV4 and myeloid sarcoma.